Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

IOVA

Iovance Biotherapeutics Inc

Dec 12 • 04:00PM ET

7.96

Dollar change -0.62
Percentage change -7.23	%

Healthcare • Biotechnology • USA • NASD

Peers: BMRN FATE CARA PRTA CRSP EDIT SGMO QURE ADAP NTLA

| Held by: VTI VB IWM XBI VBR VXF IWO IBB VTWO SCHA

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.50	Insider Own	18.94%	Shs Outstand	304.62M	Perf Week	-6.02%
Market Cap	2.43B	Forward P/E	-	EPS next Y	-0.83	Insider Trans	-0.09%	Shs Float	247.05M	Perf Month	-17.85%
Income	-410.00M	PEG	-	EPS next Q	-0.26	Inst Own	68.47%	Short Float	23.04%	Perf Quarter	-23.02%
Sales	90.86M	P/S	26.70	EPS this Y	33.29%	Inst Trans	1.73%	Short Ratio	9.42	Perf Half Y	-5.58%
Book/sh	2.54	P/B	3.14	EPS next Y	34.44%	ROA	-44.48%	Short Interest	56.92M	Perf Year	24.57%
Cash/sh	1.30	P/C	6.10	EPS next 5Y	-	ROE	-56.65%	52W Range	6.00 - 18.33	Perf YTD	-2.09%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-8.25%	ROI	-48.76%	52W High	-56.57%	Beta	0.53
Dividend TTM	-	Quick Ratio	3.90	Sales past 5Y	0.00%	Gross Margin	-19.74%	52W Low	32.67%	ATR (14)	0.54
Dividend Ex-Date	-	Current Ratio	4.22	EPS Y/Y TTM	28.07%	Oper. Margin	-473.22%	RSI (14)	36.23	Volatility	5.41% 5.52%
Employees	557	Debt/Eq	0.10	Sales Y/Y TTM	12751.20%	Profit Margin	-451.25%	Recom	1.40	Target Price	23.77
Option/Short	Yes / Yes	LT Debt/Eq	0.09	EPS Q/Q	40.47%	Payout	-	Rel Volume	1.15	Prev Close	8.58
Sales Surprise	8.87%	EPS Surprise	6.32%	Sales Q/Q	12385.07%	Earnings	Nov 07 AMC	Avg Volume	6.04M	Price	7.96
SMA20	-8.26%	SMA50	-17.82%	SMA200	-24.33%	Trades		Volume	6,923,144	Change	-7.23%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-24-24	Initiated	UBS	Buy	$17
Jul-29-24	Downgrade	Piper Sandler	Overweight → Neutral	$19 → $10
Nov-20-23	Initiated	Goldman	Buy	$12
Sep-18-23	Reiterated	Barclays	Overweight	$40 → $18
May-30-23	Upgrade	Wells Fargo	Equal Weight → Overweight	$11 → $17
Mar-27-23	Resumed	Wells Fargo	Equal Weight	$11
Jan-27-23	Upgrade	Piper Sandler	Neutral → Overweight	$11 → $14
Dec-09-22	Downgrade	Goldman	Buy → Neutral	$20 → $6
Oct-31-22	Initiated	Guggenheim	Neutral
Aug-18-22	Resumed	Wells Fargo	Equal Weight	$14
Jan-28-22	Upgrade	Stifel	Hold → Buy	$23 → $25
Dec-07-21	Resumed	Cowen	Outperform
Jun-10-21	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform	$32
May-20-21	Downgrade	Piper Sandler	Overweight → Neutral	$35 → $18
May-19-21	Downgrade	Stifel	Buy → Hold
May-19-21	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
May-03-21	Initiated	Truist	Buy	$50
Apr-16-21	Initiated	Goldman	Buy	$97
Mar-08-21	Upgrade	H.C. Wainwright	Neutral → Buy	$50
Dec-15-20	Downgrade	H.C. Wainwright	Buy → Neutral

Show Previous Ratings

Dec-12-24 10:00AM	Prediction: This Stock Will Beat the Market in 2025 (Motley Fool) -7.23%
Dec-07-24 11:08AM	3 Monster Stocks to Hold for the Next 10 Years (Motley Fool)
Nov-27-24 06:30AM	Is Iovance Biotherapeutics Stock a Millionaire Maker? (Motley Fool)
Nov-26-24 04:01PM	Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer (GlobeNewswire)
Nov-23-24 11:35AM	Got $1,500? Buy Iovance Biotherapeutics Now and Don't Look Back (Motley Fool)
10:31AM	Loading…
10:31AM	Iovance Biotherapeutics, Inc. (IOVA): Among the Most Promising Cancer Stocks According to Hedge Funds (Insider Monkey)
Nov-22-24 10:00AM	2 Innovative Stocks That Could Deliver Outsize Returns (Motley Fool)
07:49AM	Iovance Biotherapeutics Inc. (IOVA): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts (Insider Monkey)
Nov-14-24 08:00AM	Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon (PR Newswire)
Nov-08-24 08:03AM	Iovance Biotherapeutics Inc (IOVA) Q3 2024 Earnings Call Highlights: Surpassing Revenue ... (GuruFocus.com) -13.80%
Nov-07-24 05:45PM	Iovance Biotherapeutics (IOVA) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:42PM	Iovance Biotherapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024 (GlobeNewswire)
Oct-31-24 04:01PM	Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2024 Financial Results Conference Call and Webcast on Thursday, November 7, 2024 (GlobeNewswire) -5.43% +7.18%
Oct-24-24 06:01PM	Why Iovance Biotherapeutics Stock Triumphed on Thursday (Motley Fool) +7.54%
11:01AM	Loading…
Oct-18-24 11:01AM	State Street Corp's Strategic Acquisition in Iovance Biotherapeutics Inc (GuruFocus.com)
Oct-16-24 07:15PM	Is Iovance Biotherapeutics Inc. (IOVA) the Most Promising Stock to Buy According to Wall Street Analysts? (Insider Monkey) +8.54%
Oct-12-24 12:28PM	Is Iovance Biotherapeutics, Inc. (IOVA) the Best Growth Stock Under $10 to Buy? (Insider Monkey)
Oct-10-24 10:39AM	Is Iovance Biotherapeutics, Inc. (IOVA) the Best Stock Under $10 With High Potential? (Insider Monkey)
Oct-09-24 08:03AM	Strong Investor Sentiment: Artisan Partners Highlights Iovance Biotherapeutics, Inc. (IOVA) (Insider Monkey)
Oct-04-24 08:30AM	Is Iovance Biotherapeutics Stock a Buy? (Motley Fool) +7.17%
Sep-26-24 08:15AM	3 Reasons to Buy Iovance Biotherapeutics Stock Like There's No Tomorrow (Motley Fool)
Sep-16-24 06:29AM	3 Things You Need to Know if You Buy Iovance Biotherapeutics Today (Motley Fool) -5.13%
Sep-14-24 05:32PM	Iovance Biotherapeutics, Inc. (IOVA): Short Seller Sentiment is Bearish on This Cancer Stock (Insider Monkey)
Sep-06-24 09:30AM	This Is the Biggest Risk With Iovance Biotherapeutics Stock (Motley Fool)
Sep-03-24 05:00PM	Iovance Biotherapeutics to Present at Upcoming Conferences (GlobeNewswire) -6.95%
Sep-02-24 06:15PM	3 Monster Biotech Stocks to Buy Before 2025 (Motley Fool)
Aug-27-24 04:36AM	Up 47% in 2024: Where Will Iovance Biotherapeutics Be in 5 Years? (Motley Fool)
Aug-16-24 05:00PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +6.57%
Aug-14-24 07:15AM	This 1 Big Risk Is Also 1 Big Opportunity for Iovance Biotherapeutics Stock (Motley Fool) -5.87%
12:23PM	Loading…
Aug-09-24 12:23PM	Why Iovance Biotherapeutics Shares Are Soaring Today (Motley Fool) +24.94%
09:27AM	Iovance (IOVA) Q2 Earnings Beat, Stock Up on Upbeat Sales View (Zacks)
Aug-08-24 05:30PM	Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +8.32%
04:24PM	Iovance Biotherapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2024 (GlobeNewswire)
Aug-01-24 10:01AM	Iovance Biotherapeutics (IOVA) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks) -6.53%
Jul-31-24 05:31AM	Iovance Biotherapeutics Attracted a Downgrade. Is It Time to Sell? (Motley Fool)
Jul-29-24 06:24PM	Why Iovance Biotherapeutics Stock Stumbled Today (Motley Fool)
04:01PM	Iovance Biotherapeutics to Host Second Quarter and First Half 2024 Financial Results Conference Call and Webcast on Thursday, August 8, 2024 (GlobeNewswire)
08:31AM	Heres Why Iovance Biotherapeutics (IOVA) Declined in Q2 (Insider Monkey)
Jul-19-24 05:00PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-17-24 02:29PM	7 Death Cross Stocks That Could Be Contrarian Buys (InvestorPlace)
Jul-14-24 05:45AM	Is Iovance Biotherapeutics a Millionaire Maker? (Motley Fool)
Jul-11-24 02:23PM	3 Under-$10 Biotech Stocks That Could Make You Rich (InvestorPlace) +8.48%
Jul-08-24 06:46PM	Is Iovance Biotherapeutics, Inc. (IOVA) One of the Most Shorted Stocks Loved by Analysts? (Insider Monkey)
12:30PM	10 Most Shorted Stocks That Are Loved by Analysts (Insider Monkey)
Jun-28-24 07:00AM	Iovance Biotherapeutics Submits Marketing Authorization Application to European Medicines Agency for Lifileucel in Advanced Melanoma (GlobeNewswire)
04:05AM	Is It Too Late to Buy Iovance Biotherapeutics Stock? (Motley Fool)
Jun-21-24 05:00PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
06:36AM	3 Top Penny Stocks to Skyrocket Your Wealth in 2024 (InvestorPlace)
Jun-20-24 10:02PM	Is WSJ the Best Stock Analysis Website? (Insider Monkey)
08:47PM	15 Best Websites To Research Stocks (Insider Monkey)
Jun-10-24 10:15AM	The Case for Buying Iovance Biotherapeutics Stock Just Got Even Better. Here's Why (Motley Fool)
May-29-24 06:20AM	What Makes e.l.f. Beauty (ELF) an Investment Bet? (Insider Monkey)
04:58AM	Should You Consider Adding SharkNinja (SN) to Your Portfolio? (Insider Monkey)
May-28-24 08:14AM	Iovance Biotherapeutics (IOVA) Shares Rallied after the FDA approval of AMTAGVI (Insider Monkey)
08:06AM	Artisan Partners Small Cap Fund Trimmed Wingstop (WING) Based on Valuation Discipline (Insider Monkey)
May-24-24 04:01PM	Iovance Biotherapeutics to Present at Upcoming Conferences and Events (GlobeNewswire)
11:18AM	Iovance (IOVA) Up 5% on Updated Data From Melanoma Study (Zacks)
May-23-24 05:00PM	Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting (GlobeNewswire)
May-22-24 06:40AM	Bull Market Buys: 2 Growth Stocks to Own for the Long Run (Motley Fool)
May-17-24 05:15PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
May-16-24 09:30AM	4 Small-Cap Value Stocks That Could Go Parabolic (Motley Fool)
May-13-24 02:25PM	Truist Securities Trims Iovance Biotherapeutics' Price Target to $25 From $26, Buy Rating Maintained (MT Newswires)
12:42PM	Truist Adjusts Iovance Biotherapeutics' Price Target to $25 From $26, Keeps Buy Rating (MT Newswires)
May-11-24 10:00AM	The 3 Most Undervalued Biotech Stocks to Buy in May 2024 (InvestorPlace)
May-10-24 02:03PM	Why Iovance Stock Is Down 18% Today (Motley Fool) -18.48%
01:35PM	Iovance Biotherapeutics' Patient Selection for Amtagvi Launch Minimizing Attrition, Truist Securities Says (MT Newswires)
12:55PM	Iovance Biotherapeutics Inc (IOVA) Q1 2024 Earnings: Aligns with EPS Projections Amidst Strong ... (GuruFocus.com)
12:33PM	Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q1 2024 Earnings Call Transcript (Insider Monkey)
11:25AM	Update: Iovance Biotherapeutics Shares Fall After Q1 Revenue Misses Estimates (MT Newswires)
10:58AM	Iovance (IOVA) Q1 Earnings Surpass, Sales Lag Estimates (Zacks)
May-09-24 08:57PM	IOVA Stock Earnings: Iovance Biotherapeutics Meets EPS, Misses Revenue for Q1 2024 (InvestorPlace)
04:27PM	Iovance Biotherapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:23PM	Iovance Biotherapeutics Q1 Loss Narrows -- Shares Higher After Hours (MT Newswires)
04:01PM	Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates (GlobeNewswire)
May-06-24 09:56AM	Iovance (IOVA) Gears Up for Q1 Earnings: Here's What to Expect (Zacks)
May-01-24 06:01AM	Iovance Biotherapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Thursday, May 9, 2024 (GlobeNewswire) +6.11%
Apr-30-24 06:01AM	Iovance Biotherapeutics to Present at Upcoming Conferences (GlobeNewswire)
Apr-28-24 02:44PM	Where Will Iovance Biotherapeutics Stock Be in 5 Years? (Motley Fool)
Apr-27-24 07:00AM	The Top 3 Biotech Stocks to Buy in April 2024 (InvestorPlace)
Apr-25-24 10:30AM	3 Millionaire-Maker Biotech Stocks (Motley Fool)
09:20AM	20 Counties with the Highest Cancer Rates in the US (Insider Monkey)
Apr-24-24 04:01PM	Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meeting (GlobeNewswire)
Apr-21-24 05:08AM	These Biotech Stocks Could Soar 120% and 295%, According to Wall Street (Motley Fool)
Apr-19-24 05:15PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-17-24 09:45AM	Is Iovance Biotherapeutics Stock a Buy Now? (Motley Fool)
Apr-08-24 01:51PM	Iovance (IOVA) Stock Surges More Than 60% YTD: Here's Why (Zacks)
Apr-05-24 05:03AM	Better Growth Biotech Buy: Iovance Biotherapeutics vs CRISPR Therapeutics (Motley Fool)
Mar-29-24 11:30AM	Iovance Biotherapeutics (IOVA) Down 6.9% Since Last Earnings Report: Can It Rebound? (Zacks)
Mar-26-24 04:11AM	2 Soaring Growth Stocks That Could Climb Another 47% to 73%, According to Wall Street (Motley Fool)
Mar-23-24 09:00AM	U.S.-China Decoupling Poses Supply-Chain Risks for Drug Companies (The Wall Street Journal)
Mar-22-24 05:30PM	Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-18-24 08:01PM	7 Biotech Stocks Ready to Ride the Sectors Resurgence (InvestorPlace)
02:00AM	Forget Eli Lilly. Buy This Magnificent Biotech Stock Instead (Motley Fool)
Mar-15-24 08:18AM	Billionaire Paul Tudor Jones and Insiders Love These 10 Stocks (Insider Monkey)
Mar-07-24 06:01AM	1 Wall Street Analyst Thinks Iovance Biotherapeutics Stock Is Going to $32. Is It a Buy Around $17? (Motley Fool)
Mar-06-24 04:42AM	Iovance Biotherapeutics Stock Has 22% Upside, According to 1 Wall Street Analyst (Motley Fool)
Mar-05-24 01:00PM	FDA Lifts Clinical Hold on Iovance's (IOVA) Lung Cancer Study (Zacks)
Mar-04-24 06:30AM	Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer (GlobeNewswire)

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Vogt Frederick G	Interim CEO & General Counsel	Dec 02 '24	Option Exercise	0.00	10,417	0	214,662	Dec 04 04:31 PM
BILINSKY IGOR	Chief Operating Officer	Dec 02 '24	Option Exercise	0.00	3,516	0	59,323	Dec 04 04:30 PM
GRAF FINCKENSTEIN FRIEDRICH	Chief Medical Officer	Dec 02 '24	Option Exercise	0.00	3,906	0	64,633	Dec 04 04:30 PM
Maynard Ryan D	Director	Nov 12 '24	Option Exercise	7.45	50,000	372,500	57,500	Nov 14 05:00 PM
Maynard Ryan D	Director	Nov 12 '24	Sale	10.06	50,000	503,000	7,500	Nov 14 05:00 PM
Maynard Ryan D	Director	Nov 12 '24	Proposed Sale	10.06	50,000	503,104		Nov 12 07:11 PM
Vogt Frederick G	Interim CEO & General Counsel	Oct 14 '24	Option Exercise	0.00	20,834	0	213,096	Oct 16 06:33 PM
GRAF FINCKENSTEIN FRIEDRICH	Chief Medical Officer	Oct 14 '24	Option Exercise	0.00	2,813	0	62,155	Oct 16 06:32 PM
BILINSKY IGOR	Chief Operating Officer	Oct 14 '24	Option Exercise	0.00	2,813	0	57,235	Oct 16 06:30 PM
Vogt Frederick G	Interim CEO & General Counsel	Sep 03 '24	Option Exercise	0.00	57,292	0	212,175	Sep 05 07:56 PM
GRAF FINCKENSTEIN FRIEDRICH	Chief Medical Officer	Sep 03 '24	Option Exercise	0.00	27,345	0	71,233	Sep 05 07:54 PM
BILINSKY IGOR	Chief Operating Officer	Sep 03 '24	Option Exercise	0.00	26,954	0	66,313	Sep 05 07:53 PM
Bellemin Jean-Marc	Chief Financial Officer	Sep 03 '24	Option Exercise	0.00	23,438	0	41,239	Sep 05 07:52 PM
Vogt Frederick G	Interim CEO & General Counsel	Jul 15 '24	Option Exercise	0.00	20,835	0	168,160	Jul 17 08:01 PM
GRAF FINCKENSTEIN FRIEDRICH	Chief Medical Officer	Jul 15 '24	Option Exercise	0.00	2,813	0	47,299	Jul 17 08:01 PM
BILINSKY IGOR	Chief Operating Officer	Jul 15 '24	Option Exercise	0.00	2,813	0	42,571	Jul 17 08:00 PM
GRAF FINCKENSTEIN FRIEDRICH	Chief Medical Officer	Jun 03 '24	Option Exercise	0.00	3,906	0	46,468	Jun 05 08:07 PM
BILINSKY IGOR	Chief Operating Officer	Jun 03 '24	Option Exercise	0.00	3,516	0	41,542	Jun 05 08:05 PM
Vogt Frederick G	Interim CEO & General Counsel	Jun 03 '24	Option Exercise	0.00	10,417	0	151,751	Jun 05 08:04 PM
Vogt Frederick G	Interim CEO & General Counsel	Apr 15 '24	Option Exercise	0.00	20,834	0	150,185	Apr 17 07:08 PM
GRAF FINCKENSTEIN FRIEDRICH	Chief Medical Officer	Apr 15 '24	Option Exercise	0.00	2,812	0	43,989	Apr 17 07:07 PM
BILINSKY IGOR	Chief Operating Officer	Apr 15 '24	Option Exercise	0.00	2,812	0	39,453	Apr 17 07:07 PM
GRAF FINCKENSTEIN FRIEDRICH	Chief Medical Officer	Mar 04 '24	Option Exercise	0.00	15,623	0	49,230	Mar 06 06:20 PM
Vogt Frederick G	Interim CEO & General Counsel	Mar 04 '24	Option Exercise	0.00	41,662	0	140,800	Mar 06 06:19 PM
MCPEAK MERRILL A	Director	Feb 20 '24	Buy	9.15	250,000	2,287,500	320,150	Feb 20 07:52 PM
Dukes Iain D.	Director	Feb 20 '24	Buy	9.15	32,000	292,800	54,000	Feb 20 04:21 PM
Rothbaum Wayne P.	Director	Feb 20 '24	Buy	9.15	5,000,000	45,750,000	28,067,333	Feb 20 04:11 PM
Vogt Frederick G	Interim CEO & General Counsel	Jan 16 '24	Option Exercise	0.00	20,834	0	105,668	Jan 18 06:09 PM
GRAF FINCKENSTEIN FRIEDRICH	Chief Medical Officer	Jan 16 '24	Option Exercise	0.00	2,813	0	35,184	Jan 18 06:09 PM
BILINSKY IGOR	Chief Operating Officer	Jan 16 '24	Option Exercise	0.00	2,813	0	31,444	Jan 18 06:07 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IOVA

Iovance Biotherapeutics Inc

Upgrade your FINVIZ experience